首页> 外文期刊>Nature >Translation from unconventional 5 ' start sites drives tumour initiation
【24h】

Translation from unconventional 5 ' start sites drives tumour initiation

机译:非常规5'起始位点的翻译驱动肿瘤的发生

获取原文
获取原文并翻译 | 示例
           

摘要

We are just beginning to understand how translational control affects tumour initiation and malignancy. Here we use an epidermis-specific, in vivo ribosome profiling strategy to investigate the translational landscape during the transition from normal homeostasis to malignancy. Using a mouse model of inducible SOX2, which is broadly expressed in oncogenic RAS-associated cancers, we show that despite widespread reductions in translation and protein synthesis, certain oncogenic mRNAs are spared. During tumour initiation, the translational apparatus is redirected towards unconventional upstream initiation sites, enhancing the translational efficiency of oncogenic mRNAs. An in vivo RNA interference screen of translational regulators revealed that depletion of conventional eIF2 complexes has adverse effects on normal but not oncogenic growth. Conversely, the alternative initiation factor eIF2A is essential for cancer progression, during which it mediates initiation at these upstream sites, differentially skewing translation and protein expression. Our findings unveil a role for the translation of 5' untranslated regions in cancer, and expose new targets for therapeutic intervention.
机译:我们才刚刚开始了解翻译控制如何影响肿瘤的发生和恶性肿瘤。在这里,我们使用表皮特异的体内核糖体谱分析策略来研究从正常体内稳态向恶性肿瘤过渡期间的翻译情况。使用在致癌RAS相关癌中广泛表达的可诱导SOX2小鼠模型,我们显示,尽管翻译和蛋白质合成水平普遍下降,但某些致癌mRNA仍可幸免。在肿瘤启动过程中,翻译设备被重定向至非常规上游启动位点,从而增强了致癌mRNA的翻译效率。对翻译调节因子的体内RNA干扰筛选显示,常规eIF2复合物的耗竭对正常生长而不是致癌生长有不利影响。相反,替代起始因子eIF2A对于癌症进展至关重要,在此过程中,它介导这些上游位点的起始,差异化翻译和蛋白质表达。我们的发现揭示了癌症5'非翻译区翻译的作用,并揭示了治疗干预的新靶标。

著录项

  • 来源
    《Nature》 |2017年第7638期|494-499|共6页
  • 作者单位

    Rockefeller Univ, Robin Chemers Neustein Lab Mammalian Dev & Cell B, Howard Hughes Med Inst, New York, NY 10065 USA;

    Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, Howard Hughes Med Inst, San Francisco, CA 94158 USA;

    Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, Howard Hughes Med Inst, San Francisco, CA 94158 USA;

    Rockefeller Univ, Robin Chemers Neustein Lab Mammalian Dev & Cell B, Howard Hughes Med Inst, New York, NY 10065 USA;

    Rockefeller Univ, Robin Chemers Neustein Lab Mammalian Dev & Cell B, Howard Hughes Med Inst, New York, NY 10065 USA;

    Rockefeller Univ, Robin Chemers Neustein Lab Mammalian Dev & Cell B, Howard Hughes Med Inst, New York, NY 10065 USA;

    Rockefeller Univ, Robin Chemers Neustein Lab Mammalian Dev & Cell B, Howard Hughes Med Inst, New York, NY 10065 USA;

    Rockefeller Univ, Prote Resource Ctr, New York, NY 10065 USA;

    Rockefeller Univ, Robin Chemers Neustein Lab Mammalian Dev & Cell B, Howard Hughes Med Inst, New York, NY 10065 USA|Mt Sinai Hosp, Lunenfeld Tanenbaum Res Inst, Toronto, ON M5G 1X5, Canada;

    Rockefeller Univ, Prote Resource Ctr, New York, NY 10065 USA;

    Univ Calif San Francisco, Dept Cellular & Mol Pharmacol, Howard Hughes Med Inst, San Francisco, CA 94158 USA;

    Rockefeller Univ, Robin Chemers Neustein Lab Mammalian Dev & Cell B, Howard Hughes Med Inst, New York, NY 10065 USA;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号